Postprandial Glucose Levels Are Better Associated with the Risk Factors for Diabetes Compared to Fasting Glucose and Glycosylated Hemoglobin (HbA1c) Levels in Elderly Prediabetics: Beneficial Effects of Polyherbal Supplements-A Randomized, Double-Blind, Placebo Controlled Trial

Jingfen Zhu, Guoqiang Xing, Tian Shen, Gang Xu, Yun Peng, Jianyu Rao, Rong Shi, Jingfen Zhu, Guoqiang Xing, Tian Shen, Gang Xu, Yun Peng, Jianyu Rao, Rong Shi

Abstract

Backgrounds: Prediabetes is a condition in which a person's blood glucose levels are higher than normal physiological levels but lower compared to patients with diabetes. Up to 70% of individuals with prediabetes will eventually develop diabetes. To date, there have been no pharmaceutical drugs to treat diabetes. It is believed that early diagnosis and nonpharmacological intervention for prediabetes are critical for effective prevention of diabetes. Most individuals with prediabetes remain undiagnosed even after being evaluated using the standard tests for fasting glucose (FG) and HbA1c. We investigated if postprandial glucose levels (2h-PG) were associated with pre/diabetes and if polyherbal supplements could be beneficial for individuals with prediabetes.

Materials and methods: 100 elderly individuals with impaired 2h-PG or fasting glucose levels were recruited to receive either a 12-week supplement of GlucoVita (an antioxidative polyherbal formulation) (n=50) or placebo (n=50).

Results: No baseline differences were observed for FG, HbA1c, or 2h-PG. Individuals who received a twelve-week administration of GlucoVita supplements had significantly reduced 2h-PG (8.15±1.67 versus 7.35±2.06 mmol/l, P<0.05) levels compared to individuals in the placebo group. In addition, HbA1c levels were lower in individuals who received GlucoVita (5.81±0.49 %) compared to the individuals in the placebo group (6.00±0.51%) (P=0.08) after 12-weeks. Stratified analysis, based on impaired fasting glucose (IFG), 2h-PG, metabolic symptom, and age, demonstrated that, after the 12-week intervention, HbA1c levels were significantly lower in the GlucoVita administered group compared to the placebo group (IFG subgroup; 5.85±0.46%, n= 27 versus 6.14±0.50, n=33, P<0.05) and the metabolic symptom-free subgroup (5.73±0.45%, n=23 versus 6.04±0.52%, n=24, P<0.05). GlucoVita also reduced FG in individuals with normal 2h-PG (6.37±0.27 versus 6.08±0.38 mmol/l, P<0.05). Baseline 2h-PG levels, but not HbA1c or FG levels, were significantly correlated with body weight, waist circumference, and BMI (r=0.25, P<0.05; r=0.31, P<0.01; r=0.22, P<0.05, respectively).

Conclusion: 2h-PG levels were better associated with body weight, waist circumference, and BMI risk factors compared to FG and HbA1c levels in elderly individuals with prediabetes. Polyherbal formulation GlucoVita supplements improved 2h-PG and HbA1c levels only in elderly individuals who were overweight but were symptom-free and under 65 years of age. Due to the small cohort size of this pilot study, future studies are required to validate our findings.

References

    1. Anjana R. M., Shanthi Rani C. S., Deepa M., et al. Incidence of diabetes and prediabetes and predictors of progression among asian indians: 10-year follow-up of the chennai urban rural epidemiology study (CURES) Diabetes Care. 2015;38(8):1441–1448. doi: 10.2337/dc14-2814.
    1. Centers for Disease Control and Prevention (CDC) Awareness of prediabetes--United States, 2005-2010. MMWR: Morbidity and Mortality Weekly Report. 2013;62:209–212.
    1. Grundy S. M. Pre-diabetes, metabolic syndrome, and cardiovascular risk. Journal of the American College of Cardiology. 2012;59(7):635–643. doi: 10.1016/j.jacc.2011.08.080.
    1. Ho-Pham L. T., Nguyen U. D. T., Tran T. X., Nguyen T. V. Discordance in the diagnosis of diabetes: comparison between HbA1c and fasting plasma glucose. PLoS One. 2017;12e0182192
    1. Lo C. C., Lara J., Cheng T. C. Skin deep: enhanced variable may help explain racial disparities in type 2 diabetes and prediabetes. Diabetes Therapy. 2017;8(4):837–850. doi: 10.1007/s13300-017-0278-z.
    1. Lopez Lopez R., Fuentes Garcia R., Gonzalez-Villalpando M. E., Gonzalez-Villalpando C. Diabetic by HbA1c, normal by OGTT: a frequent finding in the mexico city diabetes study. Journal of the Endocrine Society. 2017;1:1247–1258.
    1. Savolainen O., Lind M. V., Bergström G., Fagerberg B., Sandberg A.-S., Ross A. Biomarkers of food intake and nutrient status are associated with glucose tolerance status and development of type 2 diabetes in older Swedish women. American Journal of Clinical Nutrition. 2017;106(5):1302–1310.
    1. Agarwal A., Hegde A., Yadav C., Ahmad A., Manjrekar P. A., Srikantiah R. M. Assessment of oxidative stress and inflammation in prediabetes—A hospital based cross-sectional study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2016;10(2):S123–S126. doi: 10.1016/j.dsx.2016.03.009.
    1. Lotfy M., Adeghate J., Kalasz H., Singh J., Adeghate E. Chronic complications of diabetes mellitus: a mini review. Current Diabetes Reviews. 2017;13(1):3–10. doi: 10.2174/1573399812666151016101622.
    1. Sotoudeh G., Abshirini M., Bagheri F., Siassi F., Koohdani F., Aslany Z. Higher dietary total antioxidant capacity is inversely related to prediabetes: A case-control study. Nutrition Journal . 2018;46:20–25. doi: 10.1016/j.nut.2017.08.005.
    1. Bhatti J. S., Bhatti G. K., Reddy P. H. Mitochondrial dysfunction and oxidative stress in metabolic disorders — A step towards mitochondria based therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2017;1863(5):1066–1077. doi: 10.1016/j.bbadis.2016.11.010.
    1. Haxhi J., Leto G., di Palumbo A. S., et al. Exercise at lunchtime: effect on glycemic control and oxidative stress in middle-aged men with type 2 diabetes. European Journal of Applied Physiology. 2016;116(3):573–582. doi: 10.1007/s00421-015-3317-3.
    1. Halmos T., Suba I. Alzheimer's disease and diabetes - the common pathogenesis. Neuropsychopharmacologia Hungarica. 2016;18:5–19.
    1. Jaruratanasirikul S., Thammaratchuchai S., Puwanant M., Mo-suwan L., Sriplung H. Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3–6-year cohort study in southern Thailand. Journal of Pediatric Endocrinology and Metabolism. 2016;29:1267–1275. doi: 10.1515/jpem-2016-0195.
    1. Arslan M. S., Tutal E., Sahin M., et al. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. Endocrine Journal. 2017;55(2):410–415. doi: 10.1007/s12020-016-1121-4.
    1. Eaglehouse Y. L., Venditti E. M., Kramer M. K., et al. Factors related to lifestyle goal achievement in a diabetes prevention program dissemination study. Translational Behavioral Medicine. 2017;7(4):873–880. doi: 10.1007/s13142-017-0494-0.
    1. Wennehorst K., Mildenstein K., Saliger B., et al. A comprehensive lifestyle intervention to prevent type 2 diabetes and cardiovascular diseases: the German CHIP trial. Prevention Science. 2016;17(3):386–397. doi: 10.1007/s11121-015-0623-2.
    1. Burke S. J., Karlstad M. D., Conley C. P., Reel D., Whelan J., Jason Collier J. Dietary polyherbal supplementation decreases CD3+ cell infiltration into pancreatic islets and prevents hyperglycemia in nonobese diabetic mice. Nutrition Research. 2015;35(4):328–336. doi: 10.1016/j.nutres.2014.12.003.
    1. Hirotani Y., Okumura K., Yoko U., Myotoku M. Effects of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on hyperinsulinemia and hypertriglyceridemia in prediabetic Zucker fatty rats. Drug Discoveries & Therapeutics. 2013;7:105–108. doi: 10.5582/ddt.2013.v7.3.105.
    1. Zhu X., Zhou Y., Xu Q., Wu J. Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis. Biomedicine & Pharmacotherapy. 2017;86:434–440. doi: 10.1016/j.biopha.2016.12.013.
    1. Teixeira C. C., Fuchs F. D. The efficacy of herbal medicines in clinical models: The case of jambolan. Journal of Ethnopharmacology. 2006;108(1):16–19. doi: 10.1016/j.jep.2006.07.032.
    1. Chaiyasut C., Sivamaruthi B. S., Pengkumsri N., et al. Germinated Thai black rice extract protects experimental diabetic rats from oxidative stress and other diabetes-related consequences. Pharmaceuticals. 2016;10(1)
    1. Bulboaca A., Bolboacă S. D., Sucis S. Protective effect of curcumin in fructose-induced metabolic syndrome and in streptozotocin-induced diabetes in rats. The Iranian Journal of Basic Medical Sciences. 2016;19:585–593.
    1. Zhu D., Wang H., Zhang J., et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. Journal of Molecular and Cellular Cardiology. 2015;87:138–147. doi: 10.1016/j.yjmcc.2015.07.015.
    1. Lo H. Y., Li C. C., Chen F. Y., Chen J. C., Hsiang C. Y., Ho T. Y. Gastro-resistant insulin receptor-binding peptide from momordica charantia improved the glucose tolerance in streptozotocin-induced diabetic mice via insulin receptor signaling pathway. Journal of Agricultural and Food Chemistry. 2017;65:9266–9274.
    1. Ma C., Yu H., Xiao Y., Wang H. Momordica charantia extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats. Pharmaceutical Biology. 2017;55(1):2170–2177. doi: 10.1080/13880209.2017.1396350.
    1. Mahmoud M. F., El Ashry F. E. Z. Z., El Maraghy N. N., Fahmy A. Studies on the antidiabetic activities of Momordica charantia fruit juice in streptozotocin-induced diabetic rats. Pharmaceutical Biology. 2017;55(1):758–765. doi: 10.1080/13880209.2016.1275026.
    1. Mahwish, Saeed F., Arshad M. S., Nisa M. U., Nadeem M. T., Arshad M. U. Hypoglycemic and hypolipidemic effects of different parts and formulations of bitter gourd (Momordica Charantia) Lipids in Health and Disease. 2017;16(1)
    1. Aljohi A., Matou-Nasri S., Ahmed N. Antiglycation and antioxidant properties of Momordica charantia. PLoS ONE. 2016;11(8)e0159985
    1. Yang S. J., Choi J. M., Park S. E., et al. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. The Journal of Nutritional Biochemistry. 2015;26(3):234–240. doi: 10.1016/j.jnutbio.2014.10.010.
    1. Xu X., Shan B., Liao C., Xie J., Wen P., Shi J. Anti-diabetic properties of Momordica charantia L. polysaccharide in alloxan-induced diabetic mice. International Journal of Biological Macromolecules. 2015;81:538–543. doi: 10.1016/j.ijbiomac.2015.08.049.
    1. Wang H.-Y., Kan W.-C., Cheng T.-J., Yu S.-H., Chang L.-H., Chuu J.-J. Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice. Food and Chemical Toxicology. 2014;69:347–356. doi: 10.1016/j.fct.2014.04.008.
    1. Habicht S. D., Ludwig C., Yang R. Y., Krawinkel M. B. Momordica charantia and type 2 diabetes: From in vitro to human studies. Current Diabetes Reviews. 2014;10(1):48–60. doi: 10.2174/1573399809666131126152044.
    1. Yin R. V., Lee N. C., Hirpara H., Phung O. J. The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis. Nutrition & Diabetes. 2014;4(12)e145
    1. Ooi C. P., Yassin Z., Hamid T.-A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online) 2010;2CD007845
    1. Sahib A. S. Antidiabetic and antioxidant effect of cinnamon in poorly controlled type-2 diabetic iraqi patients: a randomized, placebo-controlled clinical trial. Journal of Intercultural Ethnopharmacology. 2016;5(2):108–113. doi: 10.5455/jice.20160217044511.
    1. Zhu R., Liu H., Liu C., et al. Cinnamaldehyde in diabetes: a review of pharmacology, pharmacokinetics and safety. Pharmacological Research. 2017;122:78–89. doi: 10.1016/j.phrs.2017.05.019.
    1. Shen T., Xing G., Zhu J., et al. Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol. Lipids in Health and Disease. 2017;16(1, article 253)

Source: PubMed

3
구독하다